Table 1.

(B) Characteristics of studies (Antiangiogenic drugs+Chemo) included in network meta-analysis.

Study	ClinicalTrials.gov Identifier	Histology	Arm	No.pts	OS HR (95%CI)	PFS HR (95%CI)	Analysis Timing	AE(≥grade3)of any cause(%pts)
EYOND	NCT01364012	Non-Squamous	Bevacizumab + Chemo	138	0.68 (0.5,0.93)	0.4 (0.29,0.54)	PFS:Final	67%
			Chemo	138			OS:Final	62.00%
ECOG-4599	NCT00021060	Non-Squamous	Bevacizumab + Chemo	434	0.79 (0.67,0.92)	0.66 (0.57,0.77)	PFS:Final	NA
			Chemo	444			OS:Final	NA
MONET1	NCT00460317	Non-Squamous	Motesanib+Chemo	541	0.9 (0.78,1.04)	0.79 (0.68,0.9)	PFS:Final	73.00%
			Chemo	549			OS:Final	59%
BR29	NCT00795340	All	Cediranib+Chemo	153	0.94 (0.69,1.3)	0.91 (0.71,1.18)	PFS:Final	NA
			Chemo	153			OS:Final	NA

OS, overall survival; PFS, progress free survial.